MINT-CANDESARTAN TABLET

ประเทศ: แคนาดา

ภาษา: อังกฤษ

แหล่งที่มา: Health Canada

สารออกฤทธิ์:

CANDESARTAN CILEXETIL

มีจำหน่ายจาก:

MINT PHARMACEUTICALS INC

รหัส ATC:

C09CA06

INN (ชื่อสากล):

CANDESARTAN

ปริมาณ:

32MG

แบบฟอร์มเภสัชกรรม:

TABLET

องค์ประกอบ:

CANDESARTAN CILEXETIL 32MG

เส้นทางการบริหาร:

ORAL

หน่วยในแพ็คเกจ:

30/100/1000

ประเภทใบสั่งยา:

Prescription

พื้นที่บำบัด:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

สรุปสินค้า:

Active ingredient group (AIG) number: 0135220004; AHFS:

สถานะการอนุญาต:

APPROVED

วันที่อนุญาต:

2018-06-05

สรุปลักษณะสินค้า

MINT-CANDESARTAN Product Monograph
Page 1 of 34
PRODUCT MONOGRAPH
PR
MINT-CANDESARTAN
Candesartan Cilexetil Tablets
4 mg, 8 mg, 16 mg and 32 mg
Angiotensin II AT
1
Receptor Blocker
Mint Pharmaceuticals Inc., DATE OF REVISION:
6575 Davand Drive
November 29, 2022
Mississauga, Ontario
L5T 2M3
Submission
Control No: 265629
MINT-CANDESARTAN Product Monograph
Page 2 of 34
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION...........................................................
3
SUMMARY PRODUCT INFORMATION
..........................................................................
3
INDICATIONS AND CLINICAL
USE................................................................................
3
CONTRAINDICATIONS
....................................................................................................
3
WARNINGS AND PRECAUTIONS
...................................................................................
4
ADVERSE REACTIONS
....................................................................................................
8
DRUG
INTERACTIONS....................................................................................................13
DOSAGE AND
ADMINISTRATION.................................................................................14
OVERDOSAGE
.................................................................................................................17
ACTION AND CLINICAL PHARMACOLOGY
................................................................17
STORAGE AND
STABILITY............................................................................................20
DOSAGE FORMS, COMPOSITION AND PACKAGING
..................................................20
PART II: SCIENTIFIC
INFORMATION................................................................................21
PHARMACEUTICAL
INFORMATION.............................................................................21
CLINICAL TRIALS
..........................................................................................